Notes and analysis on the operational reality of commercializing biomedical innovation.

June 2026 — [ARTICLE] — Financial Elements in a Fume Date Calculation An operational analysis of why start-ups miscalculate cash runways, how accrual accounting masks insolvency triggers, and the explicit liabilities required to execute a controlled corporate wind-down.

December 2025 — [ARTICLE] — Initial Receiver Assessment of Director and Officer Insurance Policies A practical framework evaluating the structural overlap between D&O coverage limits, director liability, and asset recovery mechanics for a corporate estate at the onset of financial distress or regulatory enforcement.

January 2025 — [REPRINT] — Ten-Year Trends in How Early-Stage Sepsis Start-Ups Receive Investment A ten-year macro-level analysis of venture capital allocation across burgeoning healthcare technologies, exploring the distinct investment disparity between oncology and high-prevalence critical care spaces.

March 2023 — [REPRINT] — Sepsis Needs Diagnostic Start-Ups. A Lot of Them An examination of the structural, commercial, and financial hurdles facing university-based investigators attempting to translate early-stage diagnostic discoveries into viable, venture-backed innovations.

February 2020 — [TESTIMONY] — The Innovation Pipeline: From Universities to Small Businesses. An operational assessment before the U.S. House Committee on Small Business regarding capital distribution bottlenecks in technology transfer. A structural analysis of federal SBIR/STTR funding models, the alignment mismatch between academic reviewers and commercialization targets, and the mechanism’s role in scaling regional biotech ecosystems.